Skip to content

News

Recombinetics Announces Collaboration with Mayo Clinic to Develop the First-Ever Swine Models of Osteogenesis Imperfecta

October 7, 2019

Recombinetics today announced a collaborative research project with Mayo Clinic to advance Osteogenesis Imperfecta (OI) research by developing the first-ever swine models of OI. These models will help preclinical researchers better understand disease etiology and progression and provide a reliable preclinical model for establishing the safety and efficacy of new therapies that patients with OI…

Read More

Company Statement & FAQs on Plasmid Insertion Found in First Gene-Edited Bull

October 1, 2019

Recombinetics, Inc. has recently been the focus of a series of media stories highlighting the discovery by the FDA of a plasmid insertion in one of the founding lines of its gene-edited, polled (hornless), cattle generated during a pilot study published in Nature Biotechnology (Carlson et al, 2016). The company did not directly screen for the…

Read More

Precision Breeding’s New Horizons

August 6, 2019
Read More

Recombinetics Awarded National Institutes of Health Funding to Develop Genetically Engineered Swine Model of Glioblastoma, the Deadliest Type of Brain Tumor

July 17, 2019

In honor of Glioblastoma Awareness Day (#GBMDay), Recombinetics today announced it has received a grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to fund the development of a novel genetically engineered swine model of glioblastoma, the most common and aggressive malignant primary brain tumor. If successful, this model…

Read More

The Alliance to End Surgical Castration of Swine Announces Precision Breeding Successes

June 19, 2019

Multiple healthy litters of naturally castrated piglets developed through precision breeding Male piglets are routinely castrated to improve the quality of meat for consumers by eliminating boar taint, an unpleasant odor, and unsavory taste. This practice is an animal well-being concern and is being banned in the European Union. In April 2018, pioneering companies in…

Read More

Acceligen and Kheiron-Biotech Announce Joint Projects Focused on Precision Breeding

June 18, 2019

Project Aims to Introduce New Commercial Traits in Cattle Derived from Elite Genetic Lines Acceligen, a Recombinetics company, and Kheiron-Biotech, a Proinvesa Group company, are teaming up on a series of projects in Argentina that intends to produce multiple animal product lines to solve existing concerns in the cattle industries. These combined efforts will leverage…

Read More

From TALENs to the Table

June 7, 2019
Read More

Recombinetics Names Dr. Tad Sonstegard the First Chief Executive Officer of Its Wholly-Owned Subsidiary, Acceligen

May 29, 2019

Today, Recombinetics named Dr. Tad Sonstegard the first Chief Executive Officer of its wholly-owned subsidiary, Acceligen.  Sonstegard will lead Acceligen’s efforts to raise capital and strategic partnerships for its products that genetically improve the health and well-being of livestock and aquaculture. With Acceligen now entering into significant commercial transactions, Sonstegard’s leadership will ensure that Acceligen…

Read More

A More Humane Livestock Industry, Brought To You By CRISPR.

March 19, 2019
Read More